Moleculin Biotech (MBRX) Receivables - Other (2019 - 2025)
Moleculin Biotech's Receivables - Other history spans 7 years, with the latest figure at $7000.0 for Q4 2025.
- Quarterly results put Receivables - Other at $7000.0 for Q4 2025, down 65.0% from a year ago — trailing twelve months through Dec 2025 was $7000.0 (down 65.0% YoY), and the annual figure for FY2025 was $7000.0, down 65.0%.
- Receivables - Other for Q4 2025 was $7000.0 at Moleculin Biotech, up from $2000.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $95000.0 in Q4 2023 to a low of $1000.0 in Q2 2025.
- The 5-year median for Receivables - Other is $5000.0 (2022), against an average of $15461.5.
- The sharpest move saw Receivables - Other tumbled 91.3% in 2022, then skyrocketed 4650.0% in 2023.
- Year by year, Receivables - Other stood at $23000.0 in 2021, then tumbled by 91.3% to $2000.0 in 2022, then skyrocketed by 4650.0% to $95000.0 in 2023, then plummeted by 78.95% to $20000.0 in 2024, then plummeted by 65.0% to $7000.0 in 2025.
- According to Business Quant data, Receivables - Other over the past three periods came in at $7000.0, $2000.0, and $1000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.